一例肾功能不全患者应用利伐沙班及伏立康唑导致鼻出血的病例分析

Analysis of A Case of Nosebleed by Rivaroxaban and Voriconazole in a Patient with Renal Isufficiency

利伐沙班是一种高选择性、直接抑制因子Xa的新型口服抗凝药,具有固定剂量、口服生物利用度高等优点,在临床上的应用日益广泛。目前利伐沙班在临床应用中缺乏监测指标,药物相互作用是否增加出血风险,目前尚很少病例报道。通过介绍一例肾功能不全的患者应用利伐沙班与伏立康唑期间发生鼻出血的病例,为利伐沙班临床安全用药提供参考。

Rivaroxaban a new oral anticoagulant with high selectivity and direct inhibitory factor Xa, it is increasingly widely used in clinical application with the advantages of fixed dose and high oral bioavailability. Currently, there is a lack of monitoring indicators in the clinical application of rivaroxaban;few cases have been reported about whether the interaction between drugs increases the risk of bleeding. A case of nosebleed during rivarroxaban and voriconazole administration in a patient with renal insufficiency was introduced to provide a reference for the safe clinical use of rivarroxaban.